FI112079B - 2-(2-amino-4-okso-tetrahydropyrido[2,3-d]-pyridiini- ja pyrimido[5,4-b][1,4]tiatsin-6-yyli)etyyli-4-metyylitien-2-yyli-L-glutamiinihappojohdannaisia - Google Patents

2-(2-amino-4-okso-tetrahydropyrido[2,3-d]-pyridiini- ja pyrimido[5,4-b][1,4]tiatsin-6-yyli)etyyli-4-metyylitien-2-yyli-L-glutamiinihappojohdannaisia Download PDF

Info

Publication number
FI112079B
FI112079B FI970317A FI970317A FI112079B FI 112079 B FI112079 B FI 112079B FI 970317 A FI970317 A FI 970317A FI 970317 A FI970317 A FI 970317A FI 112079 B FI112079 B FI 112079B
Authority
FI
Finland
Prior art keywords
compound
ethyl
oxo
formula
amino
Prior art date
Application number
FI970317A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI970317A (fi
FI970317A0 (fi
Inventor
Michael D Varney
William H Romines
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Publication of FI970317A0 publication Critical patent/FI970317A0/fi
Publication of FI970317A publication Critical patent/FI970317A/fi
Application granted granted Critical
Publication of FI112079B publication Critical patent/FI112079B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FI970317A 1994-07-28 1997-01-24 2-(2-amino-4-okso-tetrahydropyrido[2,3-d]-pyridiini- ja pyrimido[5,4-b][1,4]tiatsin-6-yyli)etyyli-4-metyylitien-2-yyli-L-glutamiinihappojohdannaisia FI112079B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28163994 1994-07-28
US08/281,639 US5608082A (en) 1994-07-28 1994-07-28 Compounds useful as antiproliferative agents and GARFT inhibitors
PCT/US1995/009519 WO1996003406A1 (en) 1994-07-28 1995-07-28 Compounds useful as antiproliferative agents and garft inhibitors
US9509519 1995-07-28

Publications (3)

Publication Number Publication Date
FI970317A0 FI970317A0 (fi) 1997-01-24
FI970317A FI970317A (fi) 1997-03-05
FI112079B true FI112079B (fi) 2003-10-31

Family

ID=23078167

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970317A FI112079B (fi) 1994-07-28 1997-01-24 2-(2-amino-4-okso-tetrahydropyrido[2,3-d]-pyridiini- ja pyrimido[5,4-b][1,4]tiatsin-6-yyli)etyyli-4-metyylitien-2-yyli-L-glutamiinihappojohdannaisia

Country Status (20)

Country Link
US (2) US5608082A (pt)
EP (1) EP0773943B1 (pt)
JP (1) JPH10503762A (pt)
KR (1) KR100380610B1 (pt)
CN (2) CN1091770C (pt)
AT (1) ATE206122T1 (pt)
AU (1) AU697138B2 (pt)
CA (1) CA2195420A1 (pt)
DE (1) DE69522945T2 (pt)
DK (1) DK0773943T3 (pt)
ES (1) ES2162933T3 (pt)
FI (1) FI112079B (pt)
MX (1) MX9700675A (pt)
NO (1) NO308248B1 (pt)
NZ (1) NZ290703A (pt)
PT (1) PT773943E (pt)
RU (1) RU2152945C2 (pt)
SI (1) SI0773943T1 (pt)
TW (1) TW432062B (pt)
WO (1) WO1996003406A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831100A (en) * 1995-06-07 1998-11-03 Agouron Pharmaceuticals, Inc. Syntheses of optically pure compounds useful as GARFT inhibitors and their intermediates
WO2001016121A1 (en) * 1999-08-31 2001-03-08 Merck & Co., Inc. Heterocyclic compounds and methods of use thereof
US6774138B2 (en) 1999-08-31 2004-08-10 Merck & Co., Inc. Thiazolyl(pyridyl)ethyne compounds
AU2002306413A1 (en) * 2001-02-16 2002-10-15 Eli Lilly And Company Use of pyrido`2,3-d pyrimidin derivatives for the treatment of human cytomegalovirus infections
US6962922B2 (en) * 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
MXPA04002537A (es) 2001-10-12 2004-05-31 Warner Lambert Co Alquinos como inhibidores de metaloproteinasa de matriz.
WO2003033478A1 (en) * 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkynylated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitors
WO2003033477A1 (en) * 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkynlated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitor
US20040043959A1 (en) * 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
US6894057B2 (en) * 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US20040006077A1 (en) * 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
AU2003249505A1 (en) * 2002-07-17 2004-02-02 Warner-Lambert Company Llc Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
WO2004113337A1 (en) * 2003-06-25 2004-12-29 Pfizer Inc. Convergent synthesis of a garft inhibitor containing a methyl substitute thiophene core and a tetrahydropyrido`2,3-d! pyrimidine ring system and intermediates therefor
WO2004113328A1 (en) * 2003-06-25 2004-12-29 Pfizer Inc. Convergent asymmetric synthesis route to produce a key intermediate towards the synthesis of a garft inhibitor
WO2005016926A1 (en) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
MX2007013304A (es) 2005-04-26 2007-12-13 Pfizer Anticuerpos de p-caderina.
MY164457A (en) 2005-09-07 2017-12-15 Amgen Fremont Inc Human monoclonal antibodies to activin receptor-like kinase-1
RS20080525A (en) 2006-05-09 2009-09-08 Pfizer Products Inc., Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
US8252804B2 (en) * 2008-10-01 2012-08-28 Duquesne University Of The Holy Spirit Selective proton coupled folate transporter and folate receptor, and GARFTase inhibitor compounds and methods of using the same
ES2594409T3 (es) 2011-02-23 2016-12-20 Lupin Limited Derivados de heteroarilo como moduladores del nAChR á7
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
WO2013005153A1 (en) 2011-07-05 2013-01-10 Lupin Limited Biaryl derivatives as nachr modulators
US20140309275A1 (en) * 2011-09-29 2014-10-16 Emory University Sphingosine Analogs, Compositions, and Methods Related Thereto
IN2014MN01756A (pt) 2012-03-06 2015-07-03 Lupin Ltd
GB2543550A (en) 2015-10-21 2017-04-26 Hox Therapeutics Ltd Peptides
CN115634228B (zh) * 2021-07-20 2024-03-19 首都医科大学 嘌呤合成抑制剂在制备治疗缺血和缺血再灌注损伤药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT376436B (de) * 1982-11-05 1984-11-26 Laevosan Gmbh & Co Kg Verfahren zur herstellung neuer thiophen-2carbons[urederivate und pharmazeutisch vertraeglicher saeure- oder basenadditionssalze davon
US4927828A (en) * 1985-03-08 1990-05-22 The Trustees Of Princeton University Diastereoisomeric tetrahydropyrido-(2,3,d) pyrimidine derivatives
US4684653A (en) * 1985-03-08 1987-08-04 The Trustees Of Princeton University Pyrido(2,3-d)pyrimidine derivatives
US5026851A (en) * 1985-03-08 1991-06-25 The Trustees Of Princeton University Pyrido[2,3-]pyrimidine derivatives
US4831037A (en) * 1987-04-20 1989-05-16 The Trustees Of Princeton University 4 (3H)-oxo-5,6,7,8-tetrahydropyrido-(2,3-d)pyrimidine derivatives
US4988813A (en) * 1986-10-20 1991-01-29 The Trustees Of Princeton University Process for the preparation of fused pyridine compounds
US4895946A (en) * 1987-10-26 1990-01-23 The Trustees Of Princeton University Process for the preparation of fused pyridine compounds
US4889859A (en) * 1988-02-05 1989-12-26 The Trustees Of Princeton University Pyrido[2,3-d]pyrimidine derivatives
US4882333A (en) * 1988-05-25 1989-11-21 The Trustess Of Princeton University N-(5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl-alkanoyl)-glutamic acid derivatives
US4882334A (en) * 1988-05-25 1989-11-21 The Trustees Of Princeton University N-(5,6,7,8-tetrahydropyrido]2,3-d]pyrimidin-6-ylethl-thineyl-and furylcarbonyl)-glutamic acid derivatives
DK172753B1 (da) * 1988-05-25 1999-06-28 Lilly Co Eli N-(5,6,7,8-tetrahydropyrido[2,3--d]pyrimidin-6-yl-alkanoyl)-glutaminsyrederivater, deres anvendelse, farmaceutiske præparat
US4871746A (en) * 1988-05-31 1989-10-03 The Trustees Of Princeton University N-[N-(tetrahydropyrido[2,3-D]pyrimidinylmethyl)-aminomethylbenzoyl]glutamic acid derivatives as neoplastic growth inhibitors
US4883799A (en) * 1988-06-29 1989-11-28 The Trustees Of Princeton University N-(4-(1-hydroxy-3-(5,6,7,8-tetrahydropyrido(2,3,-d)-pyrimidin-6-yl)prop-2-yl)benzoyl)glutamic acid derivatives
EP0438261A3 (en) * 1990-01-16 1992-02-26 Takeda Chemical Industries, Ltd. Condensed heterocyclic glutamic acid derivatives, their production and use
IL99500A0 (en) * 1990-09-17 1992-08-18 Agouron Pharma Naphthalene compounds,processes for the preparation thereof and pharmaceutical compositions containing the same
US5217974A (en) * 1991-03-29 1993-06-08 Eli Lilly And Company Method for treating gar-transformylase tumors in mammals and reducing mammalian toxicity
US5223503A (en) * 1991-04-29 1993-06-29 Eli Lilly And Company 6-substituted pyrido[2,3-d]pyrimidines as antineoplastic agents
US5969136A (en) * 1992-10-15 1999-10-19 Eli Lilly And Company Cyclization for preparing antifolate compounds
CA2151588C (en) * 1992-12-16 2002-03-19 Michael D. Varney Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone

Also Published As

Publication number Publication date
EP0773943A1 (en) 1997-05-21
AU697138B2 (en) 1998-09-24
US5646141A (en) 1997-07-08
AU3151795A (en) 1996-02-22
TW432062B (en) 2001-05-01
US5608082A (en) 1997-03-04
NO970349D0 (no) 1997-01-27
DE69522945T2 (de) 2002-03-28
NO970349L (no) 1997-03-12
CA2195420A1 (en) 1996-02-08
DK0773943T3 (da) 2002-03-04
EP0773943B1 (en) 2001-09-26
DE69522945D1 (de) 2001-10-31
ATE206122T1 (de) 2001-10-15
ES2162933T3 (es) 2002-01-16
NZ290703A (en) 1998-11-25
FI970317A (fi) 1997-03-05
CN1394857A (zh) 2003-02-05
FI970317A0 (fi) 1997-01-24
CN1154110A (zh) 1997-07-09
PT773943E (pt) 2002-01-30
NO308248B1 (no) 2000-08-21
SI0773943T1 (en) 2001-12-31
CN1091770C (zh) 2002-10-02
KR100380610B1 (ko) 2003-08-27
RU2152945C2 (ru) 2000-07-20
MX9700675A (es) 1997-04-30
WO1996003406A1 (en) 1996-02-08
JPH10503762A (ja) 1998-04-07

Similar Documents

Publication Publication Date Title
FI112079B (fi) 2-(2-amino-4-okso-tetrahydropyrido[2,3-d]-pyridiini- ja pyrimido[5,4-b][1,4]tiatsin-6-yyli)etyyli-4-metyylitien-2-yyli-L-glutamiinihappojohdannaisia
KR910001136B1 (ko) 축합 이미다조피리딘 유도체의 제조방법
EP1399444B1 (fr) Composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
AU612331B2 (en) 2-substituted-e-fused-(1,2,4)triazolo(1,5-c)pyrimidines pharmaceutical compositions
US6303613B1 (en) Aminopyrimidine derivatives, processes for their preparation, compositions containing them and their use as pharmaceuticals
ES2793199T3 (es) Derivados de tetrahidroimidazopiridina como moduladores de la actividad de TNF
SK5952002A3 (en) Pyrrole derivatives as phosphodiesterase vii inhibitor, the use thereof and pharmaceutical composition comprising the same
DK164669B (da) 2- eller 3-arylsubstituerede imidazooe1,2-aaapyridiner samt fremgangsmaader til fremstilling deraf
CA1254207A (en) THERAPEUTICALLY USEFUL IMIDAZO¬1,2-.alpha.|PYRIDINE DERIVATIVES
SK6012002A3 (en) Imidazole derivative as phosphodiesterase vii inhibitor, use thereof and pharmaceutical composition containing the same
CS219256B2 (en) Method of making the derivative of the imidazothienpyrimidine
WO2015086521A1 (en) Tetrahydroimidazopyridine derivatives as modulators of tnf activity
US5723607A (en) Compounds useful as antiproliferative agents and GARFT inhibitors
PL145927B1 (en) Method of obtaining novel 1,1-alkanodiole dicarboxylates
Santagati et al. Synthesis and Activity of Phenyl Derivatives Containing 5, 6-Dimethylthieno [2, 3-d] pyrimidin-4 (1H)-one or 4H-Pyrimido [5, 4-b] indol-4-one Heterocyclic System as Potential Non-steroidal Anti-inflammatory Drugs
EP2007773B1 (de) Thiazolyl-dihydro-indazole
AU698868B2 (en) Compounds useful as antiproliferative agents and garft inhibitors
Bhattacharya et al. Studies on the synthesis of furo [3, 2-d] pyrimidine C-nucleosides: new inosine analogues with antiprotozoan activity
EP0025643B1 (en) Oxo-pyrido(1,2-a)thienopyrimidine compounds, processes for their production, and pharmaceutical compositions containing said compounds
WO2001003644A2 (en) Pyrazolopyrimidinone derivatives conjugated to thiophene moieties or benzo [fused] 5-membered heterocycles for erectile dysfunction
JPH02289574A (ja) 選択的なアデノシンレセプター化合物
GB2181129A (en) 9-(substituted thio)-4h-pyrido1,2-apyrimidin-4-one derivatives, their manufacture and us
JPS61236779A (ja) 3環式化合物
CS258500B2 (cs) Způsob výroby 4-methyl-e-methyleulfinyl-thieno[3,2-b]pyrid-7(4K)-onu
CA2195417A1 (en) Compounds useful as antiproliferative agents and garft inhibitors

Legal Events

Date Code Title Description
MA Patent expired